Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04939701 · ClinicalTrials.gov registry record · Phase 1
Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants
A Phase 1 study, sponsored by Astellas Pharma Global Development.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT04939701 is a Phase 1 study that was terminated before completion, run by Astellas Pharma Global Development. The registered enrollment target is 16 participants.
The verdict
NCT04939701, a Phase 1 study, was terminated before completion, sponsored by Astellas Pharma Global Development.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the safety, and tolerability of ASP0739, when administered as a single agent and in combination with pembrolizumab. This study also evaluated the clinical response and other measures of anticancer activity of ASP0739 when administered as a single agent and in combination with pembrolizumab based on central and local assessment.
Interventions
- DRUG ASP0739
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-12-23 |
| Est. Completion | 2023-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04939701
The ClinicalTrials.gov registry entry for NCT04939701 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ASP0739 is the first listed.
NCT04939701 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04939701 about?
NCT04939701 is a clinical study titled "Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants". The purpose of this study was to evaluate the safety, and tolerability of ASP0739, when administered as a single agent and in combination with pembrolizumab. This study also evaluated the clinical response and other measures of anticancer activity of ASP0739 when administered as a single agent and ...
What is the current status of trial NCT04939701?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2021-12-23. Estimated completion is 2023-06-01.
What interventions are being tested in trial NCT04939701?
The interventions under investigation include: ASP0739 (DRUG).
Who is sponsoring clinical trial NCT04939701?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.